p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma

Leukemia Research

Volumn 33, Issue 10, 2009, Pages 1357-1360

  Sheth, Neil ^a,b   Yeung, Joanna ^a,b   Chang, Hong ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

CD56; Extramedullary; Immunohistochemistry; Multiple myeloma; p53; Plasmacytoma

Indexed keywords

CD56 ANTIGEN; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE METASTASIS; CANCER GROWTH; CELL MIGRATION; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX DISORDER; LUNG METASTASIS; MALE; MEDIASTINUM METASTASIS; MULTIPLE MYELOMA; MUSCLE METASTASIS; MYELOMA CELL; NECK METASTASIS; PARANASAL SINUS DISEASE; PLASMA CELL; PLASMACYTOMA; PLEURA METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; SOFT TISSUE METASTASIS; TRACHEA DISEASE;

ADULT; AGED; ANTIGENS, CD56; BIOPSY; CELL CYCLE; CELL DIVISION; CELL NUCLEUS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; SEQUENCE DELETION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 67649329200     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.01.010     Document Type: Article

References (20)

1. Kremer M., Ott G., Nathrath M., Specht K., Strecker K., Alexiou C., et al. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol 205 (2005) 92-101
2. Chang H., Bartlett E.S., Patterson B., Chen C.I., and Yi Q.L. The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Hematol 129 (2005) 539-541
3. Chang H., Yeung J., Qi C., and Xu W. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous p53 deletion and poor survival for multiple myeloma. Br J Hematol 138 (2007) 324-329
4. Dahl I.M., Rasmussen T., Kauric G., and Husebekk A. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Hematol 116 (2002) 273-277
5. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., et al. Mutations in the p53 gene occur in diverse human tumor type. Nature 342 (1989) 705-708
6. Neri A., Baldini L., Trecca D., Cro L., Polli E., and Maiolo A.T. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81 (1998) 128-135
7. Chng W.J., Price-Troska T., Gonzalez-Paz N., Van Wier S., Jacobus S., Blood E., et al. Clinical significance of TP53 mutation in myeloma. Leukemia 21 (2007) 582-584
8. Van Camp B., Surie B.G., Spier C., De Waele M., Van Riet I., Vela E., et al. Plasma cell in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood 76 (1990) 377-382
9. Kaiser U., Auerbach B., and Oldenburg M. The neural cell adhesion molecule NCAM in multiple myeloma. Leuk Lymphoma 20 (1996) 389-395
10. Sahara N., Takeshita A., Shigeno K., Fujisawa S., Takeshita K., Naito K., et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Hematol 117 (2002) 882-885
11. Scholzen T., and Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 182 (2002) 311-322
12. Kanavaros P., Stefanaki K., Vlachonikolis J., Papalazarou D., Rontogianni D., Arvanitis D., et al. Immunohistochemical expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma. Anticancer Res 20 (2000) 4619-4625
13. Alexiou C., Kau R.J., Dietzfelbinger H., Kremer M., Spiess J., Schratzenstaller B., et al. Extramedullary plasmacytoma: tumour occurrence and therapeutic concepts. Cancer 85 (1999) 2305-2314
14. Chang H., Qi C., Yi Q.L., Reece D., and Stewart A.K. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 105 (2005) 358-360
15. Chang H., Stewart A.K., Qi X.Y., Li Z.H., Qi L.Y., and Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 106 (2005) 353-355
16. Kuehl W.M., and Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2 (2002) 175-187
17. Chang H., Sloan S., Li D., and Stewart A.K. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13, 1 (p53) deletions. Br J Hematol 127 (2004) 280-284
18. Chang H., Qi C., Yeung J., Reece D., Xu W., and Patterson B. Genomic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 33 (2009) 259-262
19. Pruneri G., Carboni N., Baldini L., Intini D., Colombi M., Bertolini F., et al. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation. Hum Pathol 34 (2003) 41-47
20. Lane D.P. p53, guardian of the genome. Nature 358 (1992) 15-16